Abstract
There has been only symptomatic treatment focused an amelioration of cognitive and behavioural symptoms. In clinical practice, there is a tendency to broaden the spectrum of indications in present drugs, including the treatment of early dementia stages or the treatment of different types of dementia.
Regarding the research area, multiple of brand new drug molecules reached the clinical phase. There are mentioned the most important of those molecules in this article.